Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kaye J Williams

Showing results (81-90 of 96) with videos related to

Pageof 10
Sort By:
Molecular Cancer Therapeutics|February 22, 2013
[18F]-FLT positron emission tomography can be used to image the response of sensitive tumors to PI3-kinase inhibition with the novel agent GDC-0941Christopher Cawthorne, Natalie Burrows, Roben G Gieling, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|July 15, 2020
Cardiac sub-volume targeting demonstrates regional radiosensitivity in the mouse heartMihaela Ghita, Eleanor K Gill, Gerard M Walls, et al.
BMC Cancer|May 27, 2011
Adaptation to HIF-1 deficiency by upregulation of the AMP/ATP ratio and phosphofructokinase activation in hepatomasMonika Golinska, Helen Troy, Yuen-Li Chung, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 1, 2018
Clinical Development of Novel Drug-Radiotherapy CombinationsSaif S Ahmad, Marka R Crittenden, Phuoc T Tran, et al.
Plos One|March 3, 2018
High content screening of patient-derived cell lines highlights the potential of non-standard chemotherapeutic agents for the treatment of glioblastomaKenny Kwok-Hei Yu, Jessica T Taylor, Omar N Pathmanaban, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 29, 2005
Cancer chemotherapy and drug metabolismDavid S Riddick, Chunja Lee, Shairoz Ramji, et al.
Plos One|February 18, 2015
Vasoactivity of rucaparib, a PARP-1 inhibitor, is a complex process that involves myosin light chain kinase, P2 receptors, and PARP itselfCian M McCrudden, Martin G O'Rourke, Kim E Cherry, et al.
BMC Cancer|June 7, 2024
Dose escalation of tolinapant (ASTX660) in combination with standard radical chemoradiotherapy in cervical cancer : a study protocol for a phase 1b TiTE-CRM clinical trial (CRAIN) in UK secondary care centresPeter Hoskin, Marina Lee, Denise Dunkley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 5, 2019
Oxygen-enhanced MRI Is Feasible, Repeatable, and Detects Radiotherapy-induced Change in Hypoxia in Xenograft Models and in Patients with Non-small Cell Lung CancerAhmed Salem, Ross A Little, Ayşe Latif, et al.
Journal of the National Cancer Institute|January 8, 2004
Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361Christopher R Calabrese, Robert Almassy, Stephanie Barton, et al.
Pageof 10

Showing results (81-90 of 96) with videos related to

Sort By:
Pageof 10
Molecular Cancer Therapeutics|February 22, 2013
[18F]-FLT positron emission tomography can be used to image the response of sensitive tumors to PI3-kinase inhibition with the novel agent GDC-0941Christopher Cawthorne, Natalie Burrows, Roben G Gieling, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|July 15, 2020
Cardiac sub-volume targeting demonstrates regional radiosensitivity in the mouse heartMihaela Ghita, Eleanor K Gill, Gerard M Walls, et al.
BMC Cancer|May 27, 2011
Adaptation to HIF-1 deficiency by upregulation of the AMP/ATP ratio and phosphofructokinase activation in hepatomasMonika Golinska, Helen Troy, Yuen-Li Chung, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 1, 2018
Clinical Development of Novel Drug-Radiotherapy CombinationsSaif S Ahmad, Marka R Crittenden, Phuoc T Tran, et al.
Plos One|March 3, 2018
High content screening of patient-derived cell lines highlights the potential of non-standard chemotherapeutic agents for the treatment of glioblastomaKenny Kwok-Hei Yu, Jessica T Taylor, Omar N Pathmanaban, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 29, 2005
Cancer chemotherapy and drug metabolismDavid S Riddick, Chunja Lee, Shairoz Ramji, et al.
Plos One|February 18, 2015
Vasoactivity of rucaparib, a PARP-1 inhibitor, is a complex process that involves myosin light chain kinase, P2 receptors, and PARP itselfCian M McCrudden, Martin G O'Rourke, Kim E Cherry, et al.
BMC Cancer|June 7, 2024
Dose escalation of tolinapant (ASTX660) in combination with standard radical chemoradiotherapy in cervical cancer : a study protocol for a phase 1b TiTE-CRM clinical trial (CRAIN) in UK secondary care centresPeter Hoskin, Marina Lee, Denise Dunkley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 5, 2019
Oxygen-enhanced MRI Is Feasible, Repeatable, and Detects Radiotherapy-induced Change in Hypoxia in Xenograft Models and in Patients with Non-small Cell Lung CancerAhmed Salem, Ross A Little, Ayşe Latif, et al.
Journal of the National Cancer Institute|January 8, 2004
Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361Christopher R Calabrese, Robert Almassy, Stephanie Barton, et al.
Pageof 10